SCHEMBL3722589

SCHEMBL3722589

COCOCCn1c(Br)c(C2CCCCC2)c2ccc(C(=O)OC)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
GAA P10253 2/20 0.39
HSD17B10 Q99714 2/20 0.39
HTT P42858 2/20 0.39
GLA P06280 1/20 0.39
PKM P14618 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
LMNA P02545 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HDAC1 Q13547 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
SCN9A Q15858 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772730 0.87 PKM (0.43) ALDH1A1KDM4EHPGDHTTPKM
SCHEMBL773119 0.86 JAK2 (0.42) ALDH1A1KDM4EHPGDHTTNPSR1
SCHEMBL771593 0.86 SCN9A (0.40) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL3073515 0.85 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDHTTNPSR1
SCHEMBL3085979 0.85 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL27821189 0.85 CNR2 (0.35) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL772086 0.84 KMT2A (0.40) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL4827972 0.83 ALDH1A1 (0.42) ALDH1A1KDM4EHPGDHTTNPSR1
SCHEMBL4124770 0.83 SCN9A (0.37) ALDH1A1KDM4EHPGDGAAHSD17B10
SCHEMBL10293471 0.83 ALDH1A1 (0.44) ALDH1A1KDM4EHPGDHSD17B10HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231668-A1 CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS GlaxoSmithKline LLC (US) 2010-09-29 EP disclosed
US-20090197856-A1 ANTIVIRAL COMPOUNDS GENELABS TECHNOLOGIES, INC. 2009-08-06 US disclosed
WO-2009086139-A1 CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197856-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, EIF2AK2, MAVS ALDH1A1 2216/4885KDM4E 3175/4885HPGD 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.